Compound
D1101 | spiperone
| Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| MEMBRANE POTENTIAL | 3.62±0.24 | human | qHTS-HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 3.46 | human | HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 2.92±0.24 | rat | hepatocytes | MMP assay | decrease | IC50 | 163 | |
| Pictogram | Signal | Statements | Precautionary Statement Codes |
|---|---|---|---|
  |
Warning |
Aggregated GHS information provided by 193 companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. H302 (99.48%): Harmful if swallowed [Warning Acute toxicity, oral] H361 (100%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. |
P201, P202, P264, P270, P281, P301+P312, P308+P313, P330, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) |
| 1,3,8-Triazaspiro(4.5)decan-4-one, 8-(3-(p-fluorobenzoyl)propyl)-1-phenyl- | 1,3,8-Triazaspiro(4.5)decan-4-one, 8-(4-(4-fluorophenyl)-4-oxobutyl)-1-phenyl- | 1,3,8-Triazaspiro[4.5]decan-4-one, 8-[3-(p-fluorobenzoyl)propyl]-1-phenyl- |
| 1,3,8-Triazaspiro[4.5]decan-4-one, 8-[4-(4-fluorophenyl)-4-oxobutyl]-1-phenyl- | 1,8-Triazaspiro[4.5]decan-4-one, 8-[3-(p-fluorobenzoyl)propyl]-1-phenyl- | 1,8-Triazaspiro[4.5]decan-4-one, 8-[4-(4-fluorophenyl)-4-oxobutyl]-1-phenyl- |
| 1-(4-Fluorophenyl)-4-(4-hydroxy-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-en-8-yl)-1-butanone #; | 36693-EP2272537A2 | 36693-EP2311801A1 |
| 36693-EP2311802A1 | 36693-EP2311803A1 | 36693-EP2371814A1 |
| 4-Phenyl-8-[3-(4-fluorobenzoyl)propyl]-1-oxo-2,4,8-triazaspiro[4,5]decane | 4X6E73CJ0Q | 749-02-0 |
| 8-(3-(p-Fluorobenzoyl)propyl)-1-phenyl-1,3,8-triazaspiro(4.5)decan-4-one | 8-(3-p-Fluorobenzoyl-1-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro(4,5)decane | 8-[3-(p-Fluorobenzoyl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one |
| 8-[3-(p-Fluorobenzoyl)propyl]-1-phenyl-1,8-triazaspiro[4.5]decan-4-one | 8-[4-(4-fluorophenyl)-4-keto-butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one | 8-[4-(4-fluorophenyl)-4-oxidanylidene-butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one |
| 8-[4-(4-fluorophenyl)-4-oxo-butyl]-4-phenyl-2,4,8-triazaspiro[4.5]decan-1-one | 8-[4-(4-fluorophenyl)-4-oxobutyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one | 8-[4-(4-fluorophenyl)-4-oxobutyl]-4-phenyl-2,4,8-triazaspiro[4.5]decan-1-one |
| AB00052224 | AB00052224-15 | AB00052224_16 |
| AKOS024282958 | API0004229 | BDBM21397 |
| BN0500 | BPBio1_000216 | BRD-K55468218-001-05-5 |
| BRD-K55468218-003-01-0 | BRN 0632204 | BSPBio_000196 |
| BSPBio_002959 | Butyrophenone, 4'-fluoro-4-(4-oxo-1-phenyl-1,3,8-triazaspiro(4,5)decan-8-yl)- | C23H26FN3O2 |
| CAS-749-02-0 | CCG-38975 | CHEBI:9233 |
| CHEMBL267930 | D01051 | DKGZKTPJOSAWFA-UHFFFAOYSA-N |
| DSSTox_CID_25205 | DSSTox_GSID_45205 | DSSTox_RID_80749 |
| DTXSID5045205 | DivK1c_000566 | E 525 |
| EINECS 212-024-0 | Espiperona | Espiperona [INN-Spanish] |
| FT-0674639 | GTPL3300 | GTPL99 |
| HMS1568J18 | HMS1921L09 | HMS2089E16 |
| HMS2092H17 | HMS2095J18 | HMS2235E11 |
| HMS3371L01 | HMS3712J18 | HMS501M08 |
| IDI1_000566 | KBio1_000566 | KBio2_001623 |
| KBio2_004191 | KBio2_006759 | KBio3_002459 |
| KBioGR_000862 | KBioSS_001623 | L000569 |
| LS-154780 | Lopac-S-7395 | Lopac0_001069 |
| MCULE-7534168791 | MFCD00055099 | MLS000028615 |
| MLS001076321 | NCGC00015964-01 | NCGC00015964-02 |
| NCGC00015964-03 | NCGC00015964-04 | NCGC00015964-05 |
| NCGC00015964-06 | NCGC00015964-07 | NCGC00015964-08 |
| NCGC00015964-09 | NCGC00015964-10 | NCGC00015964-11 |
| NCGC00015964-12 | NCGC00015964-13 | NCGC00015964-17 |
| NCGC00016536-01 | NCGC00022260-02 | NCGC00022260-04 |
| NCGC00022260-05 | NCGC00022260-06 | NCGC00022260-07 |
| NINDS_000566 | NSC 170983 | NSC-170983 |
| NSC-757864 | NSC170983 | NSC757864 |
| Opera_ID_1551 | Pharmakon1600-01501152 | Prestwick0_000288 |
| Prestwick1_000288 | Prestwick2_000288 | Prestwick3_000288 |
| Prestwick_624 | Q3077150 | R 5147 |
| R-5147 | REGID_for_CID_5265 | SBI-0051039.P003 |
| SCHEMBL116031 | SMR000058674 | SPBio_001532 |
| SPBio_002415 | SPECTRUM1501152 | SR-01000000261 |
| SR-01000000261-5 | SR-01000000261-8 | ST059306 |
| Spectrum2_001426 | Spectrum3_001460 | Spectrum4_000451 |
| Spectrum5_000987 | Spectrum_001143 | Spiperone (JAN/USAN) |
| Spiperone [USAN:INN:BAN:JAN] | Spiperone, solid | Spiperonum |
| Spiperonum [INN-Latin] | Spiroperidol | Spiroperidone |
| Spiroperone | Spiropitan | Spiropitan (TN) |
| Tocris-0995 | Tox21_110269 | Tox21_110269_1 |
| UNII-4X6E73CJ0Q | WLN: T6N DXTJ A3VR DF& D-& CT5MVXN EHJ DR | ZINC643233 |
| [3H]-Spiroperidol | [3H]-spiperone | [3H]spiperone |
| cid_5265 | regid855701 | spiperone |